Clinical Trial Update: GPED Regimen for Relapsed/Refractory or Advanced ENKTCL [Phase 2]

View source ↗

Summary

Phase 2 trial update for GPED regimen in relapsed/refractory or advanced Extranodal NK/T-cell Lymphoma, Nasal Type.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• GPED regimen

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type | Phase 2 | Status: UNKNOWN